PPLPHARMA — Piramal Pharma Balance Sheet
0.000.00%
- IN₹254.61bn
- IN₹297.41bn
- IN₹91.51bn
Annual balance sheet for Piramal Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | R2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 2,526 | 2,824 | 6,265 | 5,015 | 3,885 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 8,504 | 20,822 | 21,393 | 24,620 | 27,184 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 17,675 | 40,672 | 48,355 | 54,645 | 57,970 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 13,846 | 37,157 | 44,415 | 48,160 | 50,235 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 57,567 | 127,970 | 145,226 | 153,118 | 156,776 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 14,717 | 30,333 | 38,431 | 43,693 | 37,663 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 16,561 | 61,004 | 77,491 | 74,004 | 75,521 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 41,006 | 66,966 | 67,735 | 79,114 | 81,255 |
| Total Liabilities & Shareholders' Equity | 57,567 | 127,970 | 145,226 | 153,118 | 156,776 |
| Total Common Shares Outstanding |